Endocannabinoid system and mood disorders: Priming a target for new therapies

Pharmacology and Therapeutics

Volumn 138, Issue 1, 2013, Pages 18-37

  Micale, Vincenzo ^a,b,c   Di Marzo, Vincenzo ^d   Sulcova, Alexandra ^a   Wotjak, Carsten T ^b   Drago, Filippo ^c  

^a MASARYK UNIVERSITY   (Czech Republic)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c UNIVERSITY OF CATANIA   (Italy)

^d CNR   (Italy)

Author keywords

Animal models; Anxiety; CB1 receptors; Depression; Endocannabinoid system; Keywords; TRPV1 channels

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 5 METHOXY 2 METHYL 3 (2 MORPHOLINOETHYL)INDOLE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; AA 5 HT; AM 3506; AM 4113; ANANDAMIDE; ARACHIDONOYL 2' CHLOROETHYLAMIDE; CANNABICHROMENE; CANNABIDIOL; CANNABIGEROL; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID RECEPTOR AGONIST; CANNABIS; CAPSAICIN; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXANABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE; JNJ 5003; JZL 184; N (3 FURYLMETHYL)ARACHIDONAMIDE; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NESS 0327; NOLADIN ETHER; OLVANIL; PF 3845; RIMONABANT; SEROTONIN 1A RECEPTOR; SR 144258; TM 38837; UNCLASSIFIED DRUG; UNINDEXED DRUG; URB 602; VANILLOID RECEPTOR 1;

ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUTISM; COMORBIDITY; DEPRESSION; DRUG WITHDRAWAL; GENETIC VARIABILITY; HUMAN; MOOD DISORDER; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SUBSTANCE ABUSE; SUICIDAL IDEATION;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; HUMANS; MOOD DISORDERS; RECEPTORS, CANNABINOID;

EID: 84875230816     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.12.002     Document Type: Review

References (289)

1. H. Abush, and I. Akirav Cannabinoids modulate hippocampal memory and plasticity Hippocampus 20 2010 1126 1138
2. P. Adamczyk, A. Gołda, A.C. McCreary, M. Filip, and E. Przegaliński Activation of endocannabinoid transmission induces antidepressant-like effects in rats J Physiol Pharmacol 59 2008 217 228
3. C. Addy, H. Wright, K. Van Laere, I. Gantz, N. Erondu, and B.J. Musser The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake Cell Metab 7 2008 68 78
4. A. Agrawal, E.C. Nelson, A.K. Littlefield, K.K. Bucholz, L. Degenhardt, and A.K. Henders Cannabinoid receptor genotype moderation of the effects of childhood physical abuse on anhedonia and depression Arch Gen Psychiatry 69 2012 732 740
5. D.C. Aguiar, A.L. Terzian, F.S. Guimarães, and F.A. Moreira Anxiolytic-like effects induced by blockade of transient receptor potential vanilloid type 1 (TRPV1) channels in the medial prefrontal cortex of rats Psychopharmacology 205 2009 217 225
6. K. Ahn, D.S. Johnson, M. Mileni, D. Beidler, J.Z. Long, and M.K. McKinney Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain Chem Biol 16 2009 411 420
7. M.A. Akanmu, S.O. Adeosun, and O.R. Ilesanmi Neuropharmacological effects of oleamide in male and female mice Behav Brain Res 182 2007 88 94
8. N. Albelda, and D. Joel Animal models of obsessive-compulsive disorder: exploring pharmacology and neural substrates Neurosci Biobehav Rev 36 2012 47 63
9. M. Aliczki, Z. Balogh, A. Tulogdi, and J. Haller The temporal dynamics of the effects of monoacylglycerol lipase blockade on locomotion, anxiety, and body temperature Behav Pharmacol 23 2012 348 357
10. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th ed text revision 2000 American Psychiatric Press Washington, DC
11. C.H. Ashton, and P.B. Moore Endocannabinoid system dysfunction in mood and related disorders Acta Psychiatr Scand 124 2011 250 261
12. C.H. Ashton, P.B. Moore, P. Gallagher, and A.H. Young Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential J Psychopharmacol 19 2005 293 300
13. D.S. Baldwin, C. Allgulander, B. Bandelow, F. Ferre, and S. Pallanti An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder World J Biol Psychiatry 13 2012 510 516
14. F.R. Bambico, T. Cassano, S. Dominguez-Lopez, N. Katz, C.D. Walker, and D. Piomelli Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus Neuropsychopharmacology 35 2010 2083 2100
15. F.R. Bambico, P.R. Hattan, J.P. Garant, and G. Gobbi Effect of delta-9-tetrahydrocannabinol on behavioral despair and on pre- and postsynaptic serotonergic transmission Prog Neuropsychopharmacol Biol Psychiatry 38 2012 88 96
16. F.R. Bambico, N. Katz, G. Debonnel, and G. Gobbi Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex J Neurosci 27 2007 11700 11711
17. F.R. Bambico, N.T. Nguyen, N. Katz, and G. Gobbi Chronic exposure to cannabinoids during adolescence but not during adulthood impairs emotional behaviour and monoaminergic neurotransmission Neurobiol Dis 37 2010 641 655
18. F.J. Barrero, I. Ampuero, B. Morales, F. Vives, J. de Dios Luna Del Castillo, and J. Hoenicka Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1) Pharmacogenomics J 5 2005 135 141
19. B.S. Basavarajappa, R. Yalamanchili, B.F. Cravatt, T.B. Cooper, and B.L. Hungund Increased ethanol consumption and preference and decreased ethanol sensitivity in female FAAH knockout mice Neuropharmacology 50 2006 834 844
20. M. Begg, P. Pacher, S. Bátkai, D. Osei-Hyiaman, L. Offertáler, and F.M. Mo Evidence for novel cannabinoid receptors Pharmacol Ther 106 2005 133 145
21. C. Belzung, and G. Griebel Measuring normal and pathological anxiety-like behaviour in mice: a review Behav Brain Res 125 2001 141 149
22. C. Benito, E. Núñez, R.M. Tolón, E.J. Carrier, A. Rábano, and C.J. Hillard Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains J Neurosci 23 2003 11136 11141
23. M.M. Bergamaschi, R.H. Queiroz, M.H. Chagas, D.C. de Oliveira, B.S. De Martinis, and F. Kapczinski Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients Neuropsychopharmacology 36 2011 1219 1226
24. M.M. Bergamaschi, R.H. Queiroz, A.W. Zuardi, and J.A. Crippa Safety and side effects of cannabidiol, a Cannabis sativa constituent Curr Drug Saf 6 2011 237 249
25. F. Berrendero, and R. Maldonado Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol Psychopharmacology 163 2002 111 117
26. T. Bíró, B.I. Tóth, G. Haskó, R. Paus, and P. Pacher The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities Trends Pharmacol Sci 30 2009 411 420
27. T. Bisogno, L. Hanus, L. De Petrocellis, S. Tchilibon, D.E. Ponde, and I. Brandi Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide Br J Pharmacol 134 2001 845 852
28. T. Bisogno, D. Melck, L. De Petrocellis, M.Yu. Bobrov, N.M. Gretskaya, and V.V. Bezuglov Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase Biochem Biophys Res Commun 248 1998 515 522
29. R.M. Bitencourt, F.A. Pamplona, and R.N. Takahashi Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats Eur Neuropsychopharmacol 18 2008 849 859
30. M. Bortolato, P. Campolongo, R.A. Mangieri, M.L. Scattoni, R. Frau, and V. Trezza Anxiolytic-like properties of the anandamide transport inhibitor AM404 Neuropsychopharmacology 31 2006 2652 2659
31. M. Bortolato, R.A. Mangieri, J. Fu, J.H. Kim, O. Arguello, and A. Duranti Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress Biol Psychiatry 62 2007 1103 1110
32. D. Braida, V. Limonta, L. Malabarba, A. Zani, and M. Sala 5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats Eur J Pharmacol 555 2007 156 163
33. A. Busquets-Garcia, E. Puighermanal, A. Pastor, R. de la Torre, R. Maldonado, and A. Ozaita Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses Biol Psychiatry 70 2011 479 486
34. P. Campolongo, P. Ratano, A. Manduca, M.L. Scattoni, M. Palmery, and V. Trezza The endocannabinoid transport inhibitor AM404 differentially modulates recognition memory in rats depending on environmental aversiveness Front Behav Neurosci 6 2012 11
35. A.C. Campos, and F.S. Guimarães Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats Psychopharmacology 199 2008 223 230
36. A.C. Campos, and F.S. Guimarães Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids Prog Neuropsychopharmacol Biol Psychiatry 33 2009 1517 1521
37. E.J. Carrier, J.A. Auchampach, and C.J. Hillard Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression Proc Natl Acad Sci USA 103 2006 7895 7900
38. P. Casadio, C. Fernandes, R.M. Murray, and M. Di Forti Cannabis use in young people: the risk for schizophrenia Neurosci Biobehav Rev 35 2011 1779 1787
39. P.C. Casarotto, F.V. Gomes, L.B. Resstel, and F.S. Guimarães Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors Behav Pharmacol 21 2010 353 358
40. P.C. Casarotto, A.L. Terzian, D.C. Aguiar, H. Zangrossi, F.S. Guimarães, and C.T. Wotjak Opposing roles for cannabinoid receptor type-1 (CB) and transient receptor potential vanilloid type-1 channel (TRPV1) on the modulation of panic-like responses in rats Neuropsychopharmacology 37 2012 478 486
41. M.G. Cascio, L.A. Gauson, L.A. Stevenson, R.A. Ross, and R.G. Pertwee Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist Br J Pharmacol 159 2010 129 141
42. B. Chakrabarti, and S. Baron-Cohen Variation in the human cannabinoid receptor CNR1 gene modulates gaze duration for happy faces Mol Autism 2 2011 10
43. X. Chen, V.S. Williamson, S.S. An, J.M. Hettema, S.H. Aggen, and M.C. Neale Cannabinoid receptor 1 gene association with nicotine dependence Arch Gen Psychiatry 65 2008 816 824
44. A. Cippitelli, G. Astarita, A. Duranti, G. Caprioli, M. Ubaldi, and S. Stopponi Endocannabinoid regulation of acute and protracted nicotine withdrawal: effect of FAAH inhibition PLoS One 6 2011 e28142
45. J.R. Clarke, J.I. Rossato, S. Monteiro, L.R. Bevilaqua, I. Izquierdo, and M. Cammarota Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory Neurobiol Learn Mem 90 2008 374 381
46. K.R. Connolly, and M.E. Thase Emerging drugs for major depressive disorder Expert Opin Emerg Drugs 17 2012 105 126
47. B. Costa, I. Bettoni, S. Petrosino, F. Comelli, G. Giagnoni, and V. Di Marzo The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl- serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice Pharmacol Res 61 2010 537 546
48. B.F. Cravatt, K. Demarest, M.P. Patricelli, M.H. Bracey, D.K. Giang, and B.R. Martin Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase Proc Natl Acad Sci USA 98 2001 9371 9376
49. B.F. Cravatt, D.K. Giang, S.P. Mayfield, D.L. Boger, R.A. Lerner, and N.B. Gilula Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides Nature 384 1996 83 87
50. J. Crawley, and F.K. Goodwin Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines Pharmacol Biochem Behav 13 1980 167 170
51. J.A. Crippa, G.N. Derenusson, T.B. Ferrari, L. Wichert-Ana, F.L. Duran, and R. Martin-Santos Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report J Psychopharmacol 25 2011 121 130
52. J.A. Crippa, A.W. Zuardi, R. Martín-Santos, S. Bhattacharyya, Z. Atakan, and P. McGuire Cannabis and anxiety: a critical review of the evidence Hum Psychopharmacol 24 2009 515 523
53. L. Cristino, L. De Petrocellis, G. Pryce, D. Baker, V. Guglielmotti, and V. Di Marzo Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain Neuroscience 139 2006 1405 1415
54. J.F. Cryan, A. Markou, and I. Lucki Assessing antidepressant activity in rodents: recent developments and future needs Trends Pharmacol Sci 23 2002 238 245
55. J.F. Cryan, C. Mombereau, and A. Vassout The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice Neurosci Biobehav Rev 29 2005 571 625
56. J.F. Cryan, and F.F. Sweeney The age of anxiety: role of animal models of anxiolytic action in drug discovery Br J Pharmacol 164 2011 1129 1161
57. J.F. Cryan, R.J. Valentino, and I. Lucki Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test Neurosci Biobehav Rev 29 2005 547 569
58. L. De Petrocellis, A. Ligresti, A.S. Moriello, M. Allarà, T. Bisogno, and S. Petrosino Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes Br J Pharmacol 163 2011 1479 1494
59. 9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour Psychopharmacology 219 2012 859 873
60. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, and G. Griffin Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1992 1946 1949
61. V. Di Marzo Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7 2008 438 455
62. V. Di Marzo "De-liver-ance" from CB(1): a way to counteract insulin resistance? Gastroenterology 142 2012 1063 1066
63. V. Di Marzo Inhibitors of endocannabinoid breakdown for pain: Not so FA(AH)cile, after all Pain 153 2012 1785 1786
64. V. Di Marzo, and S. Petrosino Endocannabinoids and the regulation of their levels in health and disease Curr Opin Lipidol 18 2007 129 140
65. V. Di Marzo, and F. Piscitelli Gut feelings about the endocannabinoid system Neurogastroenterol Motil 23 2011 391 398
66. V. Di Marzo, F. Piscitelli, and R. Mechoulam Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes Handb Exp Pharmacol 203 2011 75 104
67. J.A. DiMasi, R.W. Hansen, and H.G. Grabowski The price of innovation: new estimates of drug development costs J Health Econ 22 2003 151 185
68. T.P. Dinh, D. Carpenter, F.M. Leslie, T.F. Freund, I. Katona, and S.L. Sensi Brain monoglyceride lipase participating in endocannabinoid inactivation Proc Natl Acad Sci USA 99 2002 10819 10824
69. K. Domschke, U. Dannlowski, P. Ohrmann, B. Lawford, J. Bauer, and H. Kugel Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression Eur Neuropsychopharmacol 18 2008 751 759
70. L.M. Dono, and P.J. Currie The cannabinoid receptor CB-inverse agonist AM251 potentiates the anxiogenic activity of urocortin I in the basolateral amygdala Neuropharmacology 62 2012 192 199
71. S. Dubreucq, I. Matias, P. Cardinal, M. Häring, B. Lutz, and G. Marsicano Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice Neuropsychopharmacology 37 2012 1885 1900
72. R.S. Duman, and G.K. Aghajanian Synaptic dysfunction in depression: potential therapeutic targets Science 338 2012 68 72
73. R.S. Duman, and L.M. Monteggia A neurotrophic model for stress-related mood disorders Biol Psychiatry 59 2006 1116 1127
74. N. Egashira, T. Matsuda, E. Koushi, F. Higashihara, K. Mishima, and S. Chidori Delta(9)-tetrahydrocannabinol prolongs the immobility time in the mouse forced swim test: involvement of cannabinoid CB(1) receptor and serotonergic system Eur J Pharmacol 589 2008 117 121
75. S.A. Eisenstein, J.R. Clapper, P.V. Holmes, D. Piomelli, and A.G. Hohmann A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy Pharmacol Res 61 2010 419 429
76. A.T. El-Alfy, K. Ivey, K. Robinson, S. Ahmed, M. Radwan, and D. Slade Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L Pharmacol Biochem Behav 95 2010 434 442
77. 9-tetrahydrocannabinol and rimonabant in the olfactory bulbectomised rat model of depression Pharmacol Biochem Behav 102 2012 357 365
78. E. Engin, J. Liu, and U. Rudolph α2-containing GABA(A) receptors: a target for the development of novel treatment strategies for CNS disorders Pharmacol Ther 136 2012 142 152
79. I. Fedorova, A. Hashimoto, R.A. Fecik, M.P. Hedrick, L.O. Hanus, and D.L. Boger Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems J Pharmacol Exp Ther 299 2001 332 342
80. D. Fegley, S. Gaetani, A. Duranti, A. Tontini, M. Mor, and G. Tarzia Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation J Pharmacol Exp Ther 313 2005 352 358
81. M. Feledziak, D.M. Lambert, J. Marchand-Brynaert, and G.G. Muccioli Inhibitors of the endocannabinoid-degrading enzymes, or how to increase endocannabinoid's activity by preventing their hydrolysis Recent Pat CNS Drug Discov 7 2012 49 70
82. M.V. Fogaça, D.C. Aguiar, F.A. Moreira, and F.S. Guimarães The endocannabinoid and endovanilloid systems interact in the rat prelimbic medial prefrontal cortex to control anxiety-like behavior Neuropharmacology 63 2012 202 210
83. J. Fu, G. Bottegoni, O. Sasso, R. Bertorelli, W. Rocchia, and M. Masetti A catalytically silent FAAH-1 variant drives anandamide transport in neurons Nat Neurosci 15 2011 64 69
84. S. Galiègue, S. Mary, J. Marchand, D. Dussossoy, D. Carrière, and P. Carayon Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations Eur J Biochem 232 1995 54 61
85. Y. Gaoni, and R. Mechoulam Isolation, structure and partial synthesis of an active constituent of hashish J Am Chem Soc 86 1964 1646 1647
86. M.S. García-Gutiérrez, B. García-Bueno, S. Zoppi, J.C. Leza, and J. Manzanares Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alterations in GABA(A) receptors Br J Pharmacol 165 2012 951 964
87. G. Gobbi, F.R. Bambico, R. Mangieri, M. Bortolato, P. Campolongo, and M. Solinas Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis Proc Natl Acad Sci USA 102 2005 18620 18625
88. F.V. Gomes, P.C. Casarotto, L.B. Resstel, and F.S. Guimarães Facilitation of CB1 receptor-mediated neurotransmission decreases marble burying behavior in mice Prog Neuropsychopharmacol Biol Psychiatry 35 2011 434 438
89. F.V. Gomes, D.G. Reis, F.H. Alves, F.M. Corrêa, F.S. Guimarães, and L.B. Resstel Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of contextual fear conditioning via 5-HT1A receptors J Psychopharmacol 26 2012 104 113
90. F.V. Gomes, L.B. Resstel, and F.S. Guimarães The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors Psychopharmacology 213 2011 465 473
91. J.P. Gong, E.S. Onaivi, H. Ishiguro, Q.R. Liu, P.A. Tagliaferro, and A. Brusco Cannabinoid CB2 receptors: immunohistochemical localization in rat brain Brain Res 1071 2006 10 23
92. E.M. Granjeiro, F.V. Gomes, F.S. Guimarães, F.M. Corrêa, and L.B. Resstel Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress Pharmacol Biochem Behav 99 2011 743 748
93. G. Griebel, J. Stemmelin, and B. Scatton Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents Biol Psychiatry 57 2005 261 267
94. L. Grinspoon, and J.B. Bakalar The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research J Psychoactive Drugs 30 1998 171 177
95. F.S. Guimarães, T.M. Chiaretti, F.G. Graeff, and A.W. Zuardi Antianxiety effect of cannabidiol in the elevated plus-maze Psychopharmacology 100 1990 558 559
96. O. Gunduz-Cinar, K.P. Macpherson, R. Cinar, J. Gamble-George, K. Sugden, and B. Williams Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity Mol Psychiatry 2012 10.1038/mp.2012.72 (Jun 12)
97. J. Haller, N. Bakos, M. Szirmay, C. Ledent, and T.F. Freund The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety Eur J Neurosci 16 2002 1395 1398
98. J. Haller, I. Barna, B. Barsvari, K. Gyimesi Pelczer, S. Yasar, and L.V. Panlilio Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats Psychopharmacology 204 2009 607 616
99. J. Haller, F. Mátyás, K. Soproni, B. Varga, B. Barsy, and B. Németh Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission Eur J Neurosci 25 2007 2445 2456
100. M. Häring, G. Marsicano, B. Lutz, and K. Monory Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice Neuroscience 146 2007 1212 1219
101. T. Hayase Depression-related anhedonic behaviors caused by immobilization stress: a comparison with nicotine-induced depression-like behavioral alterations and effects of nicotine and/or "antidepressant" drugs J Toxicol Sci 36 2011 31 41
102. T. Hayase Differential effects of TRPV1 receptor ligands against nicotine-induced depression-like behaviors BMC Pharmacol 11 2011 6
103. E. Heyman, F.X. Gamelin, M. Goekint, F. Piscitelli, B. Roelands, and E. Leclair Intense exercise increases circulating endocannabinoid and BDNF levels in humans - possible implications for reward and depression Psychoneuroendocrinology 37 2012 844 851
104. M.N. Hill, and B.B. Gorzalka Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test Eur Neuropsychopharmacol 15 2005 593 599
105. M.N. Hill, C.J. Hillard, F.R. Bambico, S. Patel, B.B. Gorzalka, and G. Gobbi The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants Trends Pharmacol Sci 30 2009 484 493
106. M.N. Hill, E.S. Karacabeyli, and B.B. Gorzalka Estrogen recruits the endocannabinoid system to modulate emotionality Psychoneuroendocrinology 32 2007 350 357
107. M.N. Hill, S.A. Kumar, S.B. Filipski, M. Iverson, K.L. Stuhr, and J.M. Keith Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure Mol Psychiatry 2012 10.1038/mp.2012.90 (Jul 10)
108. M.N. Hill, G.E. Miller, W.S. Ho, B.B. Gorzalka, and C.J. Hillard Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report Pharmacopsychiatry 41 2008 48 53
109. A.J. Hill, C.M. Williams, B.J. Whalley, and G.J. Stephens Phytocannabinoids as novel therapeutic agents in CNS disorders Pharmacol Ther 133 2012 79 97
110. C.J. Hillard, and A. Jarrahian Cellular accumulation of anandamide: consensus and controversy Br J Pharmacol 140 2003 802 808
111. W.S. Ho, M.N. Hill, G.E. Miller, B.B. Gorzalka, and C.J. Hillard Serum contents of endocannabinoids are correlated with blood pressure in depressed women Lipids Health Dis 11 2012 32
112. A.C. Howlett, M. Bidaut-Russell, W.A. Devane, L.S. Melvin, M.R. Johnson, and M. Herkenham The cannabinoid receptor: biochemical, anatomical and behavioral characterization Trends Neurosci 13 1990 420 423
113. Y.T. Hsiao, P.L. Yi, C.L. Li, and F.C. Chang Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats Neuropharmacology 62 2012 373 384
114. B. Hu, H. Doods, R.D. Treede, and A. Ceci Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833 Pain 143 2009 206 212
115. J.P. Huggins, T.S. Smart, S. Langman, L. Taylor, and T. Young An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee Pain 153 2012 1837 1846
116. B.L. Hungund, K.Y. Vinod, S.A. Kassir, B.S. Basavarajappa, R. Yalamanchili, and T.B. Cooper Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims Mol Psychiatry 9 2004 184 190
117. H. Isbell, C.W. Gorodetzsky, D. Jasinski, U. Claussen, F. von Spulak, and F. Korte Effects of (-) delta-9-trans-tetrahydrocannabinol in man Psychopharmacologia 11 1967 184 188
118. L. Iversen Cannabis and the brain Brain 126 2003 1252 1270
119. A.A. Izzo, F. Borrelli, R. Capasso, V. Di Marzo, and R. Mechoulam Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb Trends Pharmacol Sci 30 2009 515 527
120. A.A. Izzo, and K.A. Sharkey Cannabinoids and the gut: new developments and emerging concepts Pharmacol Ther 126 2010 21 38
121. W. Jacob, R. Marsch, G. Marsicano, B. Lutz, and C.T. Wotjak Cannabinoid CB1 receptor deficiency increases contextual fear memory under highly aversive conditions and long-term potentiation in vivo Neurobiol Learn Mem 98 2012 47 55
122. W. Jacob, A. Yassouridis, G. Marsicano, K. Monory, B. Lutz, and C.T. Wotjak Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission Genes Brain Behav 8 2009 685 698
123. A. Jayamanne, R. Greenwood, V.A. Mitchell, S. Aslan, D. Piomelli, and C.W. Vaughan Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models Br J Pharmacol 147 2006 281 288
124. W. Jiang, Y. Zhang, L. Xiao, J. Van Cleemput, S.P. Ji, and G. Bai Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects J Clin Invest 115 2005 3104 3116
125. C.S. John, and P.J. Currie N-Arachidonoyl-serotonin in the basolateral amygdala increases anxiolytic behavior in the elevated plus maze Behav Brain Res 233 2012 382 388
126. G. Juhasz, D. Chase, E. Pegg, D. Downey, Z.G. Toth, and K. Stones CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms Neuropsychopharmacology 34 2009 2019 2027
127. K. Kamprath, G. Marsicano, J. Tang, K. Monory, T. Bisogno, and V. Di Marzo Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes J Neurosci 26 2006 6677 6686
128. K. Kamprath, W. Plendl, G. Marsicano, J.M. Deussing, W. Wurst, and B. Lutz Endocannabinoids mediate acute fear adaptation via glutamatergic neurons independently of corticotropin-releasing hormone signaling Genes Brain Behav 8 2009 203 211
129. K. Kamprath, H. Romo-Parra, M. Häring, S. Gaburro, M. Doengi, and B. Lutz Short-term adaptation of conditioned fear responses through endocannabinoid signaling in the central amygdala Neuropsychopharmacology 36 2011 652 663
130. J.W. Kasckow, J.J. Mulchahey, and T.D. Geracioti Jr. Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors Prog Neuropsychopharmacol Biol Psychiatry 28 2004 291 295
131. S. Kathuria, S. Gaetani, D. Fegley, F. Valiño, A. Duranti, and A. Tontini Modulation of anxiety through blockade of anandamide hydrolysis Nat Med 9 2003 76 81
132. J.H. Kehne, and C.K. Cain Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models Pharmacol Ther 128 2010 460 487
133. R.C. Kessler, O. Demler, R.G. Frank, M. Olfson, H.A. Pincus, and E.E. Walters Prevalence and treatment of mental disorders, 1990 to 2003 N Engl J Med 352 2005 2515 2523
134. S.G. Kinsey, S.T. O'Neal, J.Z. Long, B.F. Cravatt, and A.H. Lichtman Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay Pharmacol Biochem Behav 98 2011 21 27
135. M.S. Kipnes, P. Hollander, K. Fujioka, I. Gantz, T. Seck, and N. Erondu A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes Diabetes Obes Metab 12 2010 517 531
136. E. Kirilly, X. Gonda, and G. Bagdy CB1 receptor antagonists: new discoveries leading to new perspectives Acta Physiol 205 2012 41 60
137. M. Klugmann, V. Klippenstein, F.M. Leweke, R. Spanagel, and M. Schneider Cannabinoid exposure in pubertal rats increases spontaneous ethanol consumption and NMDA receptor associated protein levels Int J Neuropsychopharmacol 14 2011 505 517
138. D. Koethe, I.C. Llenos, J.R. Dulay, C. Hoyer, E.F. Torrey, and F.M. Leweke Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression J Neural Transm 114 2007 1055 1063
139. D.J. Kupfer, E. Frank, and M.L. Phillips Major depressive disorder: new clinical, neurobiological, and treatment perspectives Lancet 379 2012 1045 1055
140. D.A. Kupferschmidt, A.E. Newman, R. Boonstra, and S. Erb Antagonism of cannabinoid 1 receptors reverses the anxiety-like behavior induced by central injections of corticotropin-releasing factor and cocaine withdrawal Neuroscience 204 2012 125 133
141. P. Lafenêtre, F. Chaouloff, and G. Marsicano The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction Pharmacol Res 56 2007 367 381
142. J. Lazary, G. Juhasz, L. Hunyady, and G. Bagdy Personalized medicine can pave the way for the safe use of CB-receptor antagonists Trends Pharmacol Sci 32 2011 270 280
143. J. Lazary, A. Lazary, X. Gonda, A. Benko, E. Molnar, and L. Hunyady Promoter variants of the cannabinoid receptor 1 gene (CNR1) in interaction with 5-HTTLPR affect the anxious phenotype Am J Med Genet B 150B 2009 1118 1127
144. S. Lee, D.H. Kim, S.H. Yoon, and J.H. Ryu Sub-chronic administration of rimonabant causes loss of antidepressive activity and decreases doublecortin immunoreactivity in the mouse hippocampus Neurosci Lett 467 2009 111 116
145. J.I. Lemos, L.B. Resstel, and F.S. Guimarães Involvement of the prelimbic prefrontal cortex on cannabidiol-induced attenuation of contextual conditioned fear in rats Behav Brain Res 207 2010 105 111
146. D.F. Levinson, P. Holmans, R.E. Straub, M.J. Owen, D.B. Wildenauer, and P.V. Gejman Multicenter linkage study of schizophrenia candidate regions on chromosomes 5q, 6q, 10p, and 13q: schizophrenia linkage collaborative group III Am J Hum Genet 67 2000 652 663
147. F.M. Leweke, D. Piomelli, F. Pahlisch, D. Muhl, C.W. Gerth, and C. Hoyer Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia Transl Psychiatry 2 2012 e94
148. X. Li, M.A. Frye, and R.C. Shelton Review of pharmacological treatment in mood disorders and future directions for drug development Neuropsychopharmacology 37 2012 77 101
149. Q.S. Lin, Q. Yang, D.D. Liu, Z. Sun, H. Dang, and J. Liang Hippocampal endocannabinoids play an important role in induction of long-term potentiation and regulation of contextual fear memory formation Brain Res Bull 86 2011 139 145
150. S.F. Lisboa, D.G. Reis, A.L. da Silva, F.M. Corrêa, F.S. Guimarães, and L.B. Resstel Cannabinoid CB1 receptors in the medial prefrontal cortex modulate the expression of contextual fear conditioning Int J Neuropsychopharmacol 13 2010 1163 1173
151. J. Liu, L. Wang, J. Harvey-White, B.X. Huang, H.Y. Kim, and S. Luquet Multiple pathways involved in the biosynthesis of anandamide Neuropharmacology 54 2008 1 7
152. L.E. Long, R. Chesworth, X.F. Huang, I.S. McGregor, J.C. Arnold, and T. Karl A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice Int J Neuropsychopharmacol 13 2010 861 876
153. L.E. Long, R. Chesworth, X.F. Huang, A. Wong, A. Spiro, and I.S. McGregor Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice PLoS One 7 2012 e34129
154. J.Z. Long, W. Li, L. Booker, J.J. Burston, S.G. Kinsey, and J.E. Schlosburg Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects Nat Chem Biol 5 2009 37 44
155. A.D. Lopez, and C.C. Murray The global burden of disease, 1990-2020 Nat
156. D.M. Lovinger Endocannabinoid liberation from neurons in transsynaptic signaling J Mol Neurosci 33 2007 87 93
157. A.T. Lu, M.N. Ogdie, M.R. Järvelin, I.K. Moilanen, S.K. Loo, and J.T. McCracken Association of the cannabinoid receptor gene (CNR1) with ADHD and post-traumatic stress disorder Am J Med Genet B 147B 2008 1488 1494
158. R. Machado-Vieira, G. Salvadore, N. Diazgranados, and C.A. Zarate Jr. Ketamine and the next generation of antidepressants with a rapid onset of action Pharmacol Ther 123 2009 143 150
159. K. Mackie Distribution of cannabinoid receptors in the central and peripheral nervous system Handb Exp Pharmacol 168 2005 299 325
160. M. Maćkowiak, A. Chocyk, D. Dudys, and K. Wedzony Activation of CB1 cannabinoid receptors impairs memory consolidation and hippocampal polysialylated neural cell adhesion molecule expression in contextual fear conditioning Neuroscience 158 2009 1708 1716
161. I. Magen, Y. Avraham, Z. Ackerman, L. Vorobiev, R. Mechoulam, and E.M. Berry Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation J Hepatol 51 2009 528 534
162. S. Maione, L. De Petrocellis, V. de Novellis, A.S. Moriello, S. Petrosino, and E. Palazzo Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors Br J Pharmacol 150 2007 766 781
163. D.T. Malone, D. Jongejan, and D.A. Taylor Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)- tetrahydrocannabinol in rats Pharmacol Biochem Behav 93 2009 91 96
164. S.S. Manna, and S.N. Umathe Transient receptor potential vanilloid 1 channels modulate the anxiolytic effect of diazepam Brain Res 1425 2011 75 82
165. S.S. Manna, and S.N. Umathe A possible participation of transient receptor potential vanilloid type 1 channels in the antidepressant effect of fluoxetine Eur J Pharmacol 685 2012 81 90
166. C. Mannucci, M. Navarra, A. Pieratti, G.A. Russo, A.P. Caputi, and G. Calapai Interactions between endocannabinoid and serotonergic systems in mood disorders caused by nicotine withdrawal Nicotine Tob Res 13 2011 239 247
167. E.M. Marco, M.S. García-Gutiérrez, F.J. Bermúdez-Silva, F.A. Moreira, F.S. Guimarães, and J. Manzanares Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects Front Behav Neurosci 5 2011 63
168. L.J. Marnett Decoding endocannabinoid signaling Nat Chem Biol 5 2009 8 9
169. R. Marsch, E. Foeller, G. Rammes, M. Bunck, M. Kössl, and F. Holsboer Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice J Neurosci 27 2007 832 839
170. G. Marsicano, and B. Lutz Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain Eur J Neurosci 11 1999 4213 4225
171. G. Marsicano, C.T. Wotjak, S.C. Azad, T. Bisogno, G. Rammes, and M.G. Cascio The endogenous cannabinoid system controls extinction of aversive memories Nature 418 2002 530 534
172. L.A. Matsuda, S.J. Lolait, M.J. Brownstein, A.C. Young, and T.I. Bonner Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 346 1990 561 564
173. C. Mazzola, V. Micale, and F. Drago Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade Eur J Pharmacol 477 2003 219 225
174. W.T. McKinney Jr., and W.E. Bunney Jr. Animal model of depression. I. Review of evidence: implications for research Arch Gen Psychiatry 21 1969 240 248
175. R.J. McLaughlin, M.N. Hill, F.R. Bambico, K.L. Stuhr, G. Gobbi, and C.J. Hillard Prefrontal cortical anandamide signaling coordinates coping responses to stress through a serotonergic pathway Eur Neuropsychopharmacol 22 2012 664 671
176. R.J. McLaughlin, M.N. Hill, A.C. Morrish, and B.B. Gorzalka Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect Behav Pharmacol 18 2007 431 438
177. R. Mechoulam, S. Ben-Shabat, L. Hanus, M. Ligumsky, N.E. Kaminski, and A.R. Schatz Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors Biochem Pharmacol 50 1995 83 90
178. M. Metna-Laurent, E. Soria-Gómez, D. Verrier, M. Conforzi, P. Jégo, and P. Lafenêtre Bimodal control of fear-coping strategies by CB-cannabinoid receptors J Neurosci 32 2012 7109 7118
179. F.J. Meye, V. Trezza, L.J. Vanderschuren, G.M. Ramakers, and R.A. Adan Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity Mol Psychiatry 2012 10.1038/mp.2012.145 (Oct 16)
180. V. Micale, L. Cristino, A. Tamburella, S. Petrosino, G.M. Leggio, and F. Drago Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels Neuropsychopharmacology 34 2009 593 606
181. V. Micale, L. Cristino, A. Tamburella, S. Petrosino, G.M. Leggio, and F. Drago Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: possible involvement of the endocannabinoid and endovanilloid systems Neurobiol Dis 36 2009 70 80
182. V. Micale, L. Cristino, A. Tamburella, S. Petrosino, G.M. Leggio, and V. Di Marzo Enhanced cognitive performance of dopamine D3 receptor "knock-out" mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid/endovanilloid systems Pharmacol Res 61 2010 531 536
183. V. Micale, C. Mazzola, and F. Drago Endocannabinoids and neurodegenerative diseases Pharmacol Res 56 2007 382 392
184. V. Micale, P.K. Nørregaard, and C.T. Wotjak Demonstrating peripheral restriction of novel cannabinoid CB1 antagonist TM38837 by evaluating for expression of conditioned fear in mice 35th Italian Society of Pharmacology Meeting, Abstract P-5/1 2011
185. M.J. Millan Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs Neurotherapeutics 6 2009 53 77
186. A.M. Moise, S.A. Eisenstein, G. Astarita, D. Piomelli, and A.G. Hohmann An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters Psychopharmacology 200 2008 333 346
187. K. Monory, H. Blaudzun, F. Massa, N. Kaiser, T. Lemberger, and G. Schütz Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice PLoS Biol 5 2007 e269
188. F. Montecucco, and V. Di Marzo At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction Trends Pharmacol Sci 33 2012 331 340
189. P. Monteleone, M. Bifulco, G. Maina, A. Tortorella, P. Gazzerro, and M.C. Proto Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression Pharmacol Res 61 2010 400 404
190. M. Mor, S. Rivara, A. Lodola, P.V. Plazzi, G. Tarzia, and A. Duranti Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies J Med Chem 47 2004 4998 5008
191. F.A. Moreira, D.C. Aguiar, and F.S. Guimarães Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test Prog Neuropsychopharmacol Biol Psychiatry 30 2006 1466 1471
192. F.A. Moreira, D.C. Aguiar, and F.S. Guimarães Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray Neuropharmacology 52 2007 958 965
193. F.A. Moreira, D.C. Aguiar, A.L. Terzian, F.S. Guimarães, and C.T. Wotjak Cannabinoid type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and anxiety-two sides of one coin? Neuroscience 204 2012 186 192
194. F.A. Moreira, and J.A. Crippa The psychiatric side-effects of rimonabant Rev Bras Psiquiatr 31 2009 145 153
195. F.A. Moreira, M. Grieb, and B. Lutz Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression Best Pract Res Clin Endocrinol Metab 23 2009 133 144
196. F.A. Moreira, N. Kaiser, K. Monory, and B. Lutz Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors Neuropharmacology 54 2008 141 150
197. F.A. Moreira, and C.T. Wotjak Cannabinoids and anxiety Curr Top Behav Neurosci 2 2010 429 450
198. D.A. Morilak, and A. Frazer Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders Int J Neuropsychopharmacol 7 2004 193 218
199. A.C. Morrish, M.N. Hill, C.J. Riebe, and B.B. Gorzalka Protracted cannabinoid administration elicits antidepressant behavioral responses in rats: role of gender and noradrenergic transmission Physiol Behav 98 2009 118 124
200. S. Munro, K.L. Thomas, and M. Abu-Shaar Molecular characterization of a peripheral receptor for cannabinoids Nature 365 1993 61 65
201. K.M. Myers, and M. Davis Mechanisms of fear extinction Mol Psychiatry 12 2007 120 150
202. N. Naderi, A. Haghparast, A. Saber-Tehrani, N. Rezaii, A.M. Alizadeh, and A. Khani Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice Pharmacol Biochem Behav 89 2008 64 75
203. P.S. Naidu, S.A. Varvel, K. Ahn, B.F. Cravatt, B.R. Martin, and A.H. Lichtman Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality Psychopharmacology 192 2007 61 70
204. A. Navarria, A. Tamburella, V. Micale, F. Piscitelli, L. Cristino, and V. Di Marzo Antidepressant properties of a dual blocker of Fatty Acid Amide Hydrolase (FAAH) and Transient Receptor Potential Vanilloid type-1 (TRPV-1) channel under stress-related conditions Convegno monotematico SIF: I Cannabinoidi dalla biologia alla clinica, Abstract 19 2011
205. E.J. Nestler, E. Gould, H. Manji, M. Buncan, R.S. Duman, and H.K. Greshenfeld Preclinical models: status of basic research in depression Biol Psychiatry 52 2002 503 528
206. L.D. O'Brien, K.L. Wills, B. Segsworth, B. Dashney, E.M. Rock, and C.L. Limebeer Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability Pharmacol Biochem Behav 103 2013 597 602
207. E.S. Onaivi, H. Ishiguro, J.P. Gong, S. Patel, P.A. Meozzi, and L. Myers Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects PLoS One 3 2008 e1640
208. V.C. Oropeza, K. Mackie, and E.J. Van Bockstaele Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex Brain Res 1127 2007 36 44
209. A. Ortega-Alvaro, A. Aracil-Fernández, M.S. García- Gutiérrez, F. Navarrete, and J. Manzanares Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice Neuropsychopharmacology 36 2011 1489 1504
210. P. Pacher, S. Bátkai, and G. Kunos The endocannabinoid system as an emerging target of pharmacotherapy Pharmacol Rev 58 2006 389 462
211. F.A. Pamplona, R.D. Prediger, P. Pandolfo, and R.N. Takahashi The cannabinoid receptor agonist WIN 55,212-2 facilitates the extinction of contextual fear memory and spatial memory in rats Psychopharmacology 188 2006 641 649
212. D. Parolaro, N. Realini, D. Vigano, C. Guidali, and T. Rubino The endocannabinoid system and psychiatric disorders Exp Neurol 224 2010 3 14
213. S. Patel, and C.J. Hillard Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling J Pharmacol Exp Ther 318 2006 304 311
214. S. Pellow, P. Chopin, S.E. File, and M. Briley Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat J Neurosci Methods 14 1985 149 167
215. R.G. Pertwee, A.C. Howlett, M.E. Abood, S.P. Alexander, V. Di Marzo, and M.R. Elphick International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB-and CB Pharmacol Rev 62 2010 588 631
216. S. Petrosino, and V. Di Marzo FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels Curr Opin Investig Drugs 11 2010 51 62
217. D. Piomelli The molecular logic of endocannabinoid signalling Nat Rev Neurosci 4 2003 873 884
218. F. Piscitelli, and V. Di Marzo "Redundancy" of endocannabinoid inactivation: new challenges and opportunities for pain control ACS Chem Neurosci 3 2012 356 363
219. W. Plendl, and C.T. Wotjak Dissociation of within- and between-session extinction of conditioned fear J Neurosci 30 2010 4990 4998
220. R.D. Porsolt, M. Le Pichon, and M. Jalfre Depression: a new animal model sensitive to antidepressant treatments Nature 266 1977 730 732
221. C.A. Rabinak, M. Angstadt, C.S. Sripada, J.L. Abelson, I. Liberzon, and M.R. Milad Cannabinoid facilitation of fear extinction memory recall in humans Neuropharmacology 64 2013 396 402
222. D.J. Rademacher, and C.J. Hillard Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward Prog Neuropsychopharmacol Biol Psychiatry 31 2007 633 641
223. N. Realini, D. Vigano', C. Guidali, E. Zamberletti, T. Rubino, and D. Parolaro Chronic URB597 treatment at adulthood reverted most depressive-like symptoms induced by adolescent exposure to THC in female rats Neuropharmacology 60 2011 235 243
224. L.B. Resstel, S.R. Joca, F.A. Moreira, F.M. Corrêa, and F.S. Guimarães Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats Behav Brain Res 172 2006 294 298
225. B receptors in the balance of GABAergic and glutamatergic neurotransmission Neuropsychopharmacology 37 2012 2624 2634
226. K. Rickels, K. Weisman, N. Norstad, M. Singer, D. Stoltz, and A. Brown Buspirone and diazepam in anxiety: a controlled study J Clin Psychiatry 43 1982 81 86
227. C.J. Riebe, and C.T. Wotjak Endocannabinoids and stress Stress 14 2011 384 397
228. D. Riether Selective cannabinoid receptor 2 modulators: a patent review 2009-present Expert Opin Ther Pat 22 2012 495 510
229. M. Rinaldi-Carmona, F. Barth, M. Héaulme, D. Shire, B. Calandra, and C. Congy SR141716A, a potent and selective antagonist of the brain cannabinoid receptor FEBS Lett 350 1994 240 244
230. A. Roohbakhsh, S. Keshavarz, P. Hasanein, M.E. Rezvani, and A.H. Moghaddam Role of endocannabinoid system in the ventral hippocampus of rats in the modulation of anxiety-like behaviours Basic Clin Pharmacol Toxicol 105 2009 333 338
231. T. Rubino, C. Guidali, D. Viganó, N. Realini, M. Valenti, and P. Massi CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour Neuropharmacology 54 2008 151 160
232. T. Rubino, N. Realini, D. Braida, T. Alberio, V. Capurro, and D. Viganò The depressive phenotype induced in adult female rats by adolescent exposure to THC is associated with cognitive impairment and altered neuroplasticity in the prefrontal cortex Neurotox Res 15 2009 291 302
233. T. Rubino, N. Realini, C. Castiglioni, C. Guidali, D. Viganó, and E. Marras Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex Cereb Cortex 18 2008 1292 1301
234. T. Rubino, M. Sala, D. Viganó, D. Braida, C. Castiglioni, and V. Limonta Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral Delta9-tetrahydrocannabinol in rats Neuropsychopharmacology 32 2007 2036 2045
235. T. Rubino, D. Vigano', N. Realini, C. Guidali, D. Braida, and V. Capurro Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates Neuropsychopharmacology 33 2008 2760 2771
236. T. Rubino, E. Zamberletti, and D. Parolaro Adolescent exposure to cannabis as a risk factor for psychiatric disorders J Psychopharmacol 26 2012 177 188
237. E.B. Russo, A. Burnett, B. Hall, and K.K. Parker Agonistic properties of cannabidiol at 5-HT1a receptors Neurochem Res 30 2005 1037 1043
238. M. Rutkowska, and O. Jachimczuk Antidepressant-like properties of ACEA (arachidonyl-2-chloroethylamide), the selective agonist of CB1 receptors Acta Pol Pharm 61 2004 165 167
239. M. Rutkowska, J. Jamontt, and H. Gliniak Effects of cannabinoids on the anxiety-like response in mice Pharmacol Rep 58 2006 200 206
240. R.A. Sansone, and L.A. Sansone Agomelatine: a novel antidepressant Innov Clin Neurosci 8 2011 10 14
241. C.J. Santos, C.A. Stern, and L.J. Bertoglio Attenuation of anxiety-related behaviour after the antagonism of transient receptor potential vanilloid type 1 channels in the rat ventral hippocampus Behav Pharmacol 19 2008 357 360
242. J.J. Schildkraut The catecholamine hypothesis of affective disorders: a review of supporting evidence Am J Psychiatry 122 1965 509 522
243. J.E. Schlosburg, J.L. Blankman, J.Z. Long, D.K. Nomura, B. Pan, and S.G. Kinsey Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system Nat Neurosci 13 2010 1113 1119
244. N.L. Schramm-Sapyta, Y.M. Cha, S. Chaudhry, W.A. Wilson, H.S. Swartzwelder, and C.M. Kuhn Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats Psychopharmacology 191 2007 867 877
245. N.R. Sciolino, W. Zhou, and A.G. Hohmann Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats Pharmacol Res 64 2011 226 234
246. A. Seillier, T. Advani, T. Cassano, J.G. Hensler, and A. Giuffrida Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats Int J Neuropsychopharmacol 13 2010 373 386
247. A. Seillier, and A. Giuffrida Inhibition of fatty acid amide hydrolase modulates anxiety-like behavior in PCP-treated rats Pharmacol Biochem Behav 98 2011 583 586
248. C. Silvestri, A. Ligresti, and V. Di Marzo Peripheral effects of the endocannabinoid system in energy homeostasis: adipose tissue, liver and skeletal muscle Rev Endocr Metab Disord 12 2011 153 162
249. K.S. Sink, P.J. McLaughlin, J.A. Wood, C. Brown, P. Fan, and V.K. Vemuri The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats Neuropsychopharmacology 33 2008 946 955
250. K.S. Sink, K.N. Segovia, L.E. Collins, E.J. Markus, V.K. Vemuri, and A. Makriyannis The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats Pharmacol Biochem Behav 95 2010 479 484
251. K.S. Sink, K.N. Segovia, J. Sink, P.A. Randall, L.E. Collins, and M. Correa Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142 Eur Neuropsychopharmacol 20 2010 112 122
252. V.de P. Soares, A.C. Campos, V.C. Bortoli, H. Jr Zangrossi, F.S. Guimarães, and A.W. Zuardi Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors Behav Brain Res 213 2010 225 229
253. 9- tetrahydrocannabinol and the fatty acid amide inhibitor URB-597 on go/no-go auditory discrimination performance and olfactory reversal learning in rats Behav Pharmacol 22 2011 191 202
254. K. Starowicz, L. Cristino, and V. Di Marzo TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications Curr Pharm Des 14 2008 42 54
255. K. Starowicz, S. Nigam, and V. Di Marzo Biochemistry and pharmacology of endovanilloids Pharmacol Ther 114 2007 13 33
256. M.A. Steiner, G. Marsicano, E.J. Nestler, F. Holsboer, B. Lutz, and C.T. Wotjak Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice Psychoneuroendocrinology 33 2008 54 67
257. M.A. Steiner, G. Marsicano, C.T. Wotjak, and B. Lutz Conditional cannabinoid receptor type 1 mutants reveal neuron subpopulation-specific effects on behavioral and neuroendocrine stress responses Psychoneuroendocrinology 33 2008 1165 1170
258. M.A. Steiner, K. Wanisch, K. Monory, G. Marsicano, E. Borroni, and H. Bächli Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice Pharmacogenomics J 8 2008 196 208
259. C.A. Stern, L. Gazarini, R.N. Takahashi, F.S. Guimarães, and L.J. Bertoglio On disruption of fear memory by reconsolidation blockade: evidence from cannabidiol treatment Neuropsychopharmacology 37 2012 2132 2142
260. L. Steru, R. Chermat, B. Thierry, and P. Simon The tail suspension test: a new method for screening antidepressants in mice Psychopharmacology 85 1985 367 370
261. J. Suárez, P. Rivera, R. Llorente, S.Y. Romero-Zerbo, F.J. Bermúdez-Silva, and F.R. de Fonseca Early maternal deprivation induces changes on the expression of 2-AG biosynthesis and degradation enzymes in neonatal rat hippocampus Brain Res 1349 2010 162 173
262. E. Sulcova, R. Mechoulam, and E. Fride Biphasic effects of anandamide Pharmacol Biochem Behav 59 1998 347 352
263. S. Sütt, S. Raud, T. Areda, A. Reimets, S. Kõks, and E. Vasar Cat odour-induced anxiety - a study of the involvement of the endocannabinoid system Psychopharmacology 198 2008 509 520
264. I. Svízenská, P. Dubový, and A. Sulcová Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures - a short review Pharmacol Biochem Behav 90 2008 501 511
265. J. Tam, R. Cinar, J. Liu, G. Godlewski, D. Wesley, and T. Jourdan Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance Cell Metab 16 2012 167 179
266. G. Tarzia, A. Duranti, A. Tontini, G. Piersanti, M. Mor, and S. Rivara Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors J Med Chem 46 2003 2352 2360
267. A.L. Terzian, D.C. Aguiar, F.S. Guimarães, and F.A. Moreira Modulation of anxiety-like behaviour by Transient Receptor Potential Vanilloid Type 1 (TRPV1) channels located in the dorsolateral periaqueductal gray Eur Neuropsychopharmacol 19 2009 188 195
268. A.L. Terzian, F. Drago, C.T. Wotjak, and V. Micale The dopamine and cannabinoid interaction in the modulation of emotions and cognition: assessing the role of cannabinoid CB1 receptor in neurons expressing dopamine D1 receptors Front Behav Neurosci 5 2011 49
269. G. Thiemann, C.A. Watt, C. Ledent, A. Molleman, and R.U. Hasenöhrl Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain Behav Brain Res 200 2009 60 67
270. J.M. Tobin, and N.D. Lewis New psychotherapeutic agent, chlordiazepoxide. Use in treatment of anxiety states and related symptoms JAMA 174 1960 1242 1249
271. E.T. Tzavara, R.J. Davis, K.W. Perry, X. Li, C. Salhoff, and F.P. Bymaster The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions Br J Pharmacol 138 2003 544 553
272. S.N. Umathe, S.S. Manna, and N.S. Jain Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice Behav Brain Res 223 2011 125 134
273. L.F. Van Gaal, A.M. Rissanen, A.J. Scheen, O. Ziegler, and S. Rössner Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study Lancet 365 2005 1389 1397
274. M.D. Van Sickle, M. Duncan, P.J. Kingsley, A. Mouihate, P. Urbani, and K. Mackie Identification and functional characterization of brainstem cannabinoid CB2 receptors Science 310 2005 329 332
275. G. Velasco, C. Sánchez, and M. Guzmán Towards the use of cannabinoids as antitumour agents Nat Rev Cancer 12 2012 436 444
276. K.Y. Vinod, S. Xie, D. Psychoyos, B.L. Hungund, T.B. Cooper, and S.M. Tejani-Butt Dysfunction in fatty acid amide hydrolase is associated with depressive-like behavior in Wistar Kyoto rats PLoS One 7 2012 e36743
277. D. Wade Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough? Expert Rev Neurother 12 2012 9 14
278. S.J. Ward, and R.B. Raffa Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies Obesity 19 2011 1325 1334
279. X.Y. Wei, J.Y. Yang, Y.X. Dong, and C.F. Wu Anxiolytic-like effects of oleamide in group-housed and socially isolated mice Prog Neuropsychopharmacol Biol Psychiatry 31 2007 1189 1195
280. P. Willner, A. Towell, D. Sampson, S. Sophokleous, and R. Muscat Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant Psychopharmacology 93 1987 358 364
281. H.U. Wittchen, F. Jacobi, J. Rehm, A. Gustavsson, M. Svensson, and B. Jönsson The size and burden of mental disorders and other disorders of the brain in Europe 2010 Eur Neuropsychopharmacol 21 2011 655 679
282. E.H. Wong, F.I. Tarazi, and M. Shahid The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action Pharmacol Ther 126 2010 173 185
283. L.K. Wright, J. Liu, A. Nallapaneni, and C.N. Pope Behavioral sequelae following acute diisopropylfluorophosphate intoxication in rats: comparative effects of atropine and cannabinomimetics Neurotoxicol Teratol 32 2010 329 335
284. M.L. Yates, and E.L. Barker Organized trafficking of anandamide and related lipids Vitam Horm 81 2009 25 53
285. Y. Yiangou, P. Facer, P. Durrenberger, I.P. Chessell, A. Naylor, and C. Bountra COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord BMC Neurol 6 2006 12
286. A, and NMDA receptors Neuropharmacology 62 2012 1034 1043
287. T.V. Zanelati, C. Biojone, F.A. Moreira, F.S. Guimarães, and S.R. Joca Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors Br J Pharmacol 159 2010 122 128
288. C. Zanettini, L.V. Panlilio, M. Alicki, S.R. Goldberg, J. Haller, and S. Yasar Effects of endocannabinoid system modulation on cognitive and emotional behavior Front Behav Neurosci 5 2011 57
289. A. Zuardi, J. Crippa, S. Dursun, S. Morais, J. Vilela, and R. Sanches Cannabidiol was ineffective for manic episode of bipolar affective disorder J Psychopharmacol 24 2010 135 137